Publication:
Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach

Thumbnail Image

Date

2017

Journal Title

Journal ISSN

Volume Title

Publisher

Public Library of Science
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Sheehan, Deirdre F., Steven D. Criss, G. Scott Gazelle, Pari V. Pandharipande, and Chung Yin Kong. 2017. “Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach.” PLoS ONE 12 (3): e0173119. doi:10.1371/journal.pone.0173119. http://dx.doi.org/10.1371/journal.pone.0173119.

Research Data

Abstract

More than half of males in China are current smokers and evidence from western countries tells us that an unprecedented number of smoking-attributable deaths will occur as the Chinese population ages. We used the China Lung Cancer Policy Model (LCPM) to simulate effects of computed tomography (CT)-based lung cancer screening in China, comparing the impact of a screening guideline published in 2015 by a Chinese expert group to a version developed for the United States by the U.S. Centers for Medicare & Medicaid Services (CMS). The China LCPM, built using an existing lung cancer microsimulation model, can project population outcomes associated with interventions for smoking-related diseases. After calibrating the model to published Chinese smoking prevalence and lung cancer mortality rates, we simulated screening from 2016 to 2050 based on eligibility criteria from the CMS and Chinese guidelines, which differ by age to begin and end screening, pack-years smoked, and years since quitting. Outcomes included number of screens, mortality reduction, and life-years saved for each strategy. We projected that in the absence of screening, 14.98 million lung cancer deaths would occur between 2016 and 2050. Screening with the CMS guideline would prevent 0.72 million deaths and 5.8 million life-years lost, resulting in 6.58% and 1.97% mortality reduction in males and females, respectively. Screening with the Chinese guideline would prevent 0.74 million deaths and 6.6 million life-years lost, resulting in 6.30% and 2.79% mortality reduction in males and females, respectively. Through 2050, 1.43 billion screens would be required using the Chinese screening strategy, compared to 988 million screens using the CMS guideline. In conclusion, CT-based lung cancer screening implemented in 2016 and based on the Chinese screening guideline would prevent about 20,000 (2.9%) more lung cancer deaths through 2050, but would require about 445 million (44.7%) more screens than the CMS guideline.

Description

Keywords

Medicine and Health Sciences, Health Care, Health Care Policy, Screening Guidelines, Oncology, Cancers and Neoplasms, Lung and Intrathoracic Tumors, Diagnostic Medicine, Cancer Detection and Diagnosis, Cancer Screening, People and Places, Demography, Death Rates, Biology and Life Sciences, Behavior, Habits, Smoking Habits, Geographical Locations, Asia, China, Public and Occupational Health, Health Screening, Population Groupings, Ethnicities, Chinese People

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories